🔗 Visit the ClinicalTrials.gov page for NCT01780662
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. | Onco Targets Ther | 2013 | 0.85 |
| 2 | MicroRNAs in cancer therapeutics: "from the bench to the bedside". | Expert Opin Biol Ther | 2015 | 0.84 |
| 3 | Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. | Onco Targets Ther | 2014 | 0.80 |
| 4 | Immunotherapy in pediatric malignancies: current status and future perspectives. | Future Oncol | 2014 | 0.78 |
| 5 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |
| 6 | Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. | Hematology Am Soc Hematol Educ Program | 2014 | 0.75 |